Novartis Ag (NVS) Receivables (2009 - 2026)
Novartis Ag (NVS) posted Receivables of $9.6 billion for Q2 2026, down 4.39% sequentially from $10.1 billion in Q4 2025, and up 6.4% YoY from $9.1 billion in Q2 2025.
Novartis Ag (NVS) Receivables (2009 - 2026) Analysis & Trends
Novartis Ag has reported Receivables for 18 years, with the latest figure at $9.6 billion in Q2 2026.
- Quarterly Receivables rose 6.4% year-over-year to $9.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.6 billion (up 6.4% YoY) and the FY2025 annual result came in at $10.1 billion, up 18.29% from the prior year.
- Receivables retreated to $9.6 billion in Q2 2026 per NVS's latest filing, from $10.1 billion in the prior quarter.
- Over five years, Receivables peaked at $10.1 billion in Q4 2025 and troughed at $8.2 billion in Q2 2024.
- A 5-year average of $9.0 billion and a median of $9.0 billion in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables decreased 10.52% in 2024, then grew 18.29% in 2025.
- Over 5 years, Receivables stood at $9.0 billion in 2022, then declined by 7.37% to $8.4 billion in 2023, then climbed by 1.93% to $8.5 billion in 2024, then rose by 18.29% to $10.1 billion in 2025, then fell by 4.39% to $9.6 billion in 2026.
- According to Business Quant data, Receivables over the past three periods registered $9.6 billion, $10.1 billion, and $9.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.64 Bn |
| Dec 31, 2025 | 10.08 Bn |
| Jun 30, 2025 | 9.06 Bn |
| Dec 31, 2024 | 8.52 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Jun 30, 2023 | 9.20 Bn |
| Dec 31, 2022 | 9.02 Bn |
| Jun 30, 2022 | 8.64 Bn |
| Dec 31, 2021 | 8.80 Bn |
| Jun 30, 2021 | 8.40 Bn |
| Dec 31, 2020 | 9.18 Bn |
| Jun 30, 2020 | 7.64 Bn |
| Mar 31, 2020 | 109.00 Mn |
| Dec 31, 2019 | 9.47 Bn |
| Jun 30, 2019 | 4.00 Mn |
| Dec 31, 2018 | 10.09 Bn |
| Jun 30, 2018 | 8.80 Bn |
| Dec 31, 2017 | 840.00 Mn |
| Dec 31, 2016 | 872.00 Mn |